Literature DB >> 23843638

Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites.

Priyamvada Acharya1, Timothy S Luongo, Ivelin S Georgiev, Julie Matz, Stephen D Schmidt, Mark K Louder, Pascal Kessler, Yongping Yang, Krisha McKee, Sijy O'Dell, Lei Chen, Daniel Baty, Patrick Chames, Loïc Martin, John R Mascola, Peter D Kwong.   

Abstract

The conserved HIV-1 site of coreceptor binding is protected from antibody-directed neutralization by conformational and steric restrictions. While inaccessible to most human antibodies, the coreceptor site has been shown to be accessed by antibody fragments. In this study, we used X-ray crystallography, surface plasmon resonance, and pseudovirus neutralization to characterize the gp120-envelope glycoprotein recognition and HIV-1 neutralization of a heavy chain-only llama antibody, named JM4. We describe full-length IgG2b and IgG3 versions of JM4 that target the coreceptor-binding site and potently neutralize over 95% of circulating HIV-1 isolates. Contrary to established trends that show improved access to the coreceptor-binding region by smaller antibody fragments, the single-domain (VHH) version of JM4 neutralized less well than the full-length IgG2b version of JM4. The crystal structure at 2.1-Å resolution of VHH JM4 bound to HIV-1 YU2 gp120 stabilized in the CD4-bound state by the CD4-mimetic miniprotein, M48U1, revealed a JM4 epitope that combined regions of coreceptor recognition (including the gp120 bridging sheet, V3 loop, and β19 strand) with gp120 structural elements involved in recognition of CD4 such as the CD4-binding loop. The structure of JM4 with gp120 thus defines a novel CD4-induced site of vulnerability involving elements of both coreceptor- and CD4-binding sites. The potently neutralizing JM4 IgG2b antibody that targets this newly defined site of vulnerability adds to the expanding repertoire of broadly neutralizing antibodies that effectively neutralize HIV-1 and thereby potentially provides a new template for vaccine development and target for HIV-1 therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23843638      PMCID: PMC3753989          DOI: 10.1128/JVI.01332-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

2.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Authors:  Chih-Chin Huang; Son N Lam; Priyamvada Acharya; Min Tang; Shi-Hua Xiang; Syed Shahzad-Ul Hussan; Robyn L Stanfield; James Robinson; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Carole A Bewley; Peter D Kwong
Journal:  Science       Date:  2007-09-28       Impact factor: 47.728

4.  CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.

Authors:  Yven Van Herrewege; Laurence Morellato; Anne Descours; Laetitia Aerts; Jo Michiels; Leo Heyndrickx; Loïc Martin; Guido Vanham
Journal:  J Antimicrob Chemother       Date:  2008-02-12       Impact factor: 5.790

5.  Inference of macromolecular assemblies from crystalline state.

Authors:  Evgeny Krissinel; Kim Henrick
Journal:  J Mol Biol       Date:  2007-05-13       Impact factor: 5.469

6.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Authors:  Weizao Chen; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

8.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

9.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  13 in total

1.  Intracellular expression of camelid single-domain antibodies specific for influenza virus nucleoprotein uncovers distinct features of its nuclear localization.

Authors:  Joseph Ashour; Florian I Schmidt; Leo Hanke; Juanjo Cragnolini; Marco Cavallari; Arwen Altenburg; Rebeccah Brewer; Jessica Ingram; Charles Shoemaker; Hidde L Ploegh
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

2.  Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

Authors:  M Bouvin-Pley; M Morgand; L Meyer; C Goujard; A Moreau; H Mouquet; M Nussenzweig; C Pace; D Ho; P J Bjorkman; D Baty; P Chames; M Pancera; P D Kwong; P Poignard; F Barin; M Braibant
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

3.  Intracellular Neutralization of Ricin Toxin by Single-domain Antibodies Targeting the Active Site.

Authors:  Michael J Rudolph; Timothy F Czajka; Simon A Davis; Chi My Thi Nguyen; Xiao-Ping Li; Nilgun E Tumer; David J Vance; Nicholas J Mantis
Journal:  J Mol Biol       Date:  2020-01-10       Impact factor: 5.469

4.  The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.

Authors:  Lihong Liu; Weiming Wang; Julie Matz; Chaobaihui Ye; Lucie Bracq; Jerome Delon; Jason T Kimata; Zhiwei Chen; Serge Benichou; Paul Zhou
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.

Authors:  Hannah J Barbian; Julie M Decker; Frederic Bibollet-Ruche; Rachel P Galimidi; Anthony P West; Gerald H Learn; Nicholas F Parrish; Shilpa S Iyer; Yingying Li; Craig S Pace; Ruijiang Song; Yaoxing Huang; Thomas N Denny; Hugo Mouquet; Loic Martin; Priyamvada Acharya; Baoshan Zhang; Peter D Kwong; John R Mascola; C Theo Verrips; Nika M Strokappe; Lucy Rutten; Laura E McCoy; Robin A Weiss; Corrine S Brown; Raven Jackson; Guido Silvestri; Mark Connors; Dennis R Burton; George M Shaw; Michel C Nussenzweig; Pamela J Bjorkman; David D Ho; Michael Farzan; Beatrice H Hahn
Journal:  MBio       Date:  2015-04-21       Impact factor: 7.867

Review 6.  Single-Domain Antibodies As Therapeutics against Human Viral Diseases.

Authors:  Yanling Wu; Shibo Jiang; Tianlei Ying
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

7.  Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.

Authors:  Kazuki Tanaka; Takeo Kuwata; Muntasir Alam; Gilad Kaplan; Shokichi Takahama; Kristel Paola Ramirez Valdez; Anna Roitburd-Berman; Jonathan M Gershoni; Shuzo Matsushita
Journal:  Retrovirology       Date:  2017-09-22       Impact factor: 4.602

8.  IgM Antibodies Can Access Cryptic Antigens Denied to IgG: Hypothesis on Novel Binding Mechanism.

Authors:  Eric Chun Yiu Law; Danny Tze Ming Leung; Frankie Chi Hang Tam; Kitty Kit Ting Cheung; Naomi Hua Yin Cheng; Pak Leong Lim
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 9.  Antigen recognition by single-domain antibodies: structural latitudes and constraints.

Authors:  Kevin A Henry; C Roger MacKenzie
Journal:  MAbs       Date:  2018-08-15       Impact factor: 5.857

10.  Allosteric induction of the CD4-bound conformation of HIV-1 Gp120.

Authors:  Anna Roitburd-Berman; Gal Dela; Gilad Kaplan; George K Lewis; Jonathan M Gershoni
Journal:  Retrovirology       Date:  2013-12-05       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.